Form 4: Dexcom CFO Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Dexcom's Chief Financial Officer, Jereme M. Sylvain, sold 3,500 shares of common stock at $75.51 per share under a pre-arranged 10b5-1 trading plan.
Summary
- Jereme M. Sylvain, the Executive Vice President and Chief Financial Officer of Dexcom Inc., sold 3,500 shares of Dexcom common stock on November 15, 2024.
- The sale was executed at a price of $75.51 per share.
- This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on November 21, 2023, and amended on August 6, 2024.
- Following the sale, Mr. Sylvain beneficially owns 80,774 shares of Dexcom stock, which includes 49,085 unvested restricted stock units.
- These restricted stock units vest over various periods, with grants made on December 15, 2021, March 8, 2022, March 8, 2023, and March 8, 2024.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing for an executive stock sale under a pre-arranged plan. It doesn't indicate any positive or negative sentiment about the company's performance.
Risks
- Sales by executives, even under pre-arranged plans, can sometimes be perceived negatively by the market.
Industry Context
Executive stock sales are a common occurrence, especially under pre-arranged 10b5-1 plans, and are often part of executive compensation and personal financial planning. This sale is not unusual in the context of executive stock ownership.
Comparison to Industry Standards
- Many executives at publicly traded companies use 10b5-1 plans to manage their stock sales, which is a standard practice to avoid accusations of insider trading.
- The vesting schedules for restricted stock units are typical for executive compensation packages, often spanning several years to align executive interests with long-term company performance.
- The sale of 3,500 shares is a relatively small transaction compared to the total number of shares held by Mr. Sylvain, which is not unusual for executives managing their personal finances.
Stakeholder Impact
- The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, although it is a routine transaction under a pre-arranged plan.
Key Dates
| Date | Description |
|---|---|
| 12/15/2021 | Date of grant for 1,460 restricted stock units that vest through December 15, 2024. |
| 03/08/2022 | Date of grant for 7,060 restricted stock units that vest through March 8, 2025. |
| 03/08/2023 | Date of grant for 14,512 restricted stock units that vest through March 8, 2026. |
| 11/21/2023 | Date Mr. Sylvain adopted the 10b5-1 trading plan. |
| 03/08/2024 | Date of grant for 26,053 restricted stock units that vest through March 8, 2027. |
| 08/06/2024 | Date the 10b5-1 trading plan was amended. |
| 11/15/2024 | Date of the stock sale transaction. |
| 11/18/2024 | Date of the filing of the SEC Form 4. |
Keywords
Dexcom, DXCM, Jereme M. Sylvain, 10b5-1 Plan, insider trading, stock sale, executive compensation, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.